Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a pipeline of monoclonal antibodies focused on infectious disease, with the most advanced being an IND candidate for treatment of Respiratory Syncytial Virus, licensed to Medimmune.
February 14, 2013
Trellis launches its Antibody Repertoire Monitoring (ARM™) patient screening program ![]()